Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Insulin Battle Looms After EMA Panel Backs Novo’s Insulin Degludec

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.

You may also be interested in...



Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars

The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.

Investors Optimistic On FDA Panel For Novo’s Insulin Degludec

Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.

Sanofi Targets 18 Drug Launches From 2012 To 2015

Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel